# Three Domains Improved, Then One

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/three-domains-improved-then-one

> A randomized trial found semaglutide improving three cognitive domains. After adjusting for sex and immune status, one was left, at exactly the significance threshold.

## Key points

- Three domains improved unadjusted; only visuospatial survived adjustment, at P=.05.
- The paper's own conclusion is hedged and singular. The risk is in the retelling.
- Whether the analysis corrected for testing multiple domains is not stated in the abstract.
- Phase 2b, 108 people, 32 weeks, a computerized screening tool.
- 65% non-White and 40% female, more representative than this field usually manages.

A randomized trial in people living with HIV found semaglutide improving three cognitive domains at 32 weeks. Then the authors adjusted for sex and immune status, and **one** was left, at P = .05, exactly on the line.[1] Both halves of that sentence are the finding, and only the first half travels.

## Why this population

People living with HIV, even on effective antiretroviral therapy, carry higher rates of visceral fat accumulation, chronic inflammation and cognitive decline than people without HIV. Those three things are plausibly connected, and a drug that reduces the first two is a reasonable thing to test against the third.

The same group had already shown that semaglutide reduced weight, visceral fat and several inflammatory markers in this population. This trial asked whether cognition followed.

> **One thing to credit.** Of 108 participants, 65% were not white and 40% were women, with a median age of 53. That is a substantially more representative sample than trials in this field usually assemble, and findings from it generalize better as a result.

## What was found, in order

Participants on antiretroviral therapy were randomized evenly to 32 weeks of semaglutide or placebo, double-blind, with cognitive function as the primary outcome, measured using a computerized screening instrument.

*Cognitive domains, semaglutide against placebo at 32 weeks.[1]*

| Domain | Unadjusted | After adjusting for sex and CD4 count |
| --- | --- | --- |
| Visuospatial | P = .01 | **P = .05** |
| Naming and language | P = .05 | Not significant |
| Delayed recall | P = .04 | Not significant |

Adjustment is not a trick played on a result. Sex and CD4 count both plausibly relate to cognition and could differ between arms by chance in a 108-person trial; accounting for them is the more careful analysis. Two of the three findings did not survive it.

> The adjusted result is the one the authors believed, and it is a single domain sitting on the threshold.

The paper’s own conclusion says semaglutide *may* have a beneficial impact on *visuospatial* cognitive function: hedged, and singular. That is an accurate description of what the table shows. The risk here is entirely in the retelling.

## The question the abstract does not answer

> **A cognitive battery measures several domains at once, and testing several things means some will clear P < .05 by chance.** Three did here. Whether the analysis corrected for that, and if so how, is not stated in the published abstract. We cannot tell you, and we are not going to assume it either way.

It matters because of how thin the surviving margin is. A finding at exactly .05 in one of several domains, in 108 people, is the kind of result that exists to justify a larger trial rather than to change anything. That is also what a phase 2b study is for.

## The inflammation route

The authors ran a mediation analysis and reported that semaglutide’s effect on the visuospatial score persisted while accounting for changes in two inflammatory markers (C-reactive protein and soluble CD163) at P = .04, which they read as the effect running through inflammation.

Mediation analysis tests whether a hypothesis is consistent with the data. It does not establish a causal pathway, because it rests on assumptions that trial data cannot verify. We set that out at more length in [is it just the weight loss](https://glpwatchdog.org/research/is-it-just-the-weight-loss), and the same caution applies here with less data behind it.

## What to take from it

- **It is a phase 2b signal, not a treatment finding.** One domain, at the threshold, in 108 people over 32 weeks.
- **The screening instrument is not a full neuropsychological assessment.** It is designed to detect change efficiently, not to characterize it.
- **The question is worth pursuing.** The biology is coherent and the population has a real unmet need.
- **Anyone quoting “three cognitive domains improved” is quoting the unadjusted analysis** and stopping before the sentence that follows it.

## Frequently asked questions

### Does semaglutide improve cognition in people with HIV?

One domain, visuospatial function, remained statistically significant after adjustment, at P = .05. Two other domains improved before adjustment and did not survive it. The authors describe the finding as one semaglutide 'may' have.

### Why did two findings disappear after adjustment?

Sex and CD4 count both plausibly relate to cognition and can differ between arms by chance in a trial of 108 people. Accounting for them is the more careful analysis, and two of three results did not hold up under it.

### Was the analysis corrected for testing several domains?

The published abstract does not say. Testing multiple cognitive domains means some will clear the significance threshold by chance, so it matters. We cannot tell from what is published, and we are not going to assume.

### Did the effect come from reduced inflammation?

The authors conclude it did, from a mediation analysis. Mediation tests whether a hypothesis fits the data; it does not establish a causal pathway, since it rests on assumptions trial data cannot check.

### How big was the trial?

One hundred and eight participants, evenly split, over 32 weeks. It is a phase 2b study, the stage designed to decide whether a larger trial is worth running.

## References

1. Atieh O, Daher J, Abboud M, et al. Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial. Clinical Infectious Diseases. 2026. PMID: 41098140. https://pubmed.ncbi.nlm.nih.gov/41098140/

---

Cite as: GLP Watchdog, Nora Bissett, "Three Domains Improved, Then One", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/three-domains-improved-then-one

Canonical HTML page: https://glpwatchdog.org/research/three-domains-improved-then-one

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
